ResoTher Pharma Receives a €2.5 Million Grant from European Innovation Council (EIC) to Support a Phase IIa Clinical Study of Their Lead Candidate RTP-026 for Myocardial Infarction

ResoTher Pharma announced that the company has received a €2.5 million grant from the EIC to support the development of the company’s Lead Compound, RTP-026, in a Phase IIa clinical study in myocardial infarction.